Get in on Humacyte Inc’s (HUMA) buy-in window today!

With 0.96 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.94 million shares. The 52-week range on HUMA shows that it touched its highest point at $5.60 and its lowest point at $1.96 during that stretch. It currently has a 1-year price target of $7.33. Beta for the stock currently stands at 1.45.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HUMA was down-trending over the past week, with a drop of -5.41%, but this was down by -8.33% over a month. Three-month performance surged to 4.58% while six-month performance rose 1.37%. The stock gained 2.06% in the past year, while it has gained 4.58% so far this year. A look at the trailing 12-month EPS for HUMA yields -1.07 with Next year EPS estimates of -0.75. For the next quarter, that number is -0.23. This implies an EPS growth rate of 14.54% for this year and 18.47% for next year.

Float and Shares Shorts:

At present, 103.67 million HUMA shares are outstanding with a float of 86.14 million shares on hand for trading. On Mar 15, 2024, short shares totaled 3.78 million, which was 3.23% higher than short shares on Feb 15, 2024. In addition to Dr. Laura E. Niklason M.D., Ph.D. as the firm’s Founder, President, CEO & Director, Mr. Dale A. Sander serves as its CFO, Chief Corporate Development Officer & Treasurer.

Institutional Ownership:

Through their ownership of 15.54% of HUMA’s outstanding shares, institutional investors have minority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for HUMA since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.

Dividends & Yield:

In terms of dividends, HUMA has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and HUMA currently yields $0.00. In the past year, HUMA’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, HUMA has a current buyback yield of $––. This was $–– for the TTM, and it was $–– for the past five years.